12.19.25 -- 2025 GLP-1 Impacts Tell Us About CDMOs In 2026

Strategic formulation choices and early solubility screening are vital for overcoming poor solubility and limited supply to accelerate the path to first-in-human trials and stand up to the pressure.

API-in-capsule offers a fast path for early clinical data, but it can't eliminate the need for full formulation development. Weighing the potential for higher total development time and cost is critical.

Explore the complexities of producing highly potent APIs and related drug products while ensuring full GMP compliance. Case study included.

This segment of the Outsourced Pharma Live event, “Small Molecule Outsourcing: Getting Timelines, Tech Transfer and Analytics Right,” outlines how sponsors can ensure that a CDMO’s quality systems and analytical outputs meet regulatory expectations by aligning early on target regions, building audit and qualification rights into contracts, executing robust quality agreements, monitoring QMS metrics, and overseeing third-party testing vendors.

See how incorporating small amounts of SYLOID® 244 FP during micronization can significantly enhance powder flow, thereby making subsequent blending and formulation more efficient.

A well-crafted strategy isn’t just about defense. Investing early in the right controls not only minimizes risks but also accelerates timelines, streamlines regulatory interactions, and builds trust.

Spray dry technology is being leveraged to create shelf-stable, dry-powder vaccines to treat and prevent the spread of tuberculosis which could significantly improve our global response to disease.

A team of experts discuss risk-reduction strategies, critical formulation considerations, and careful technology selection to stretch the often limited quantities of API available for early studies.

To meet ambitious orphan drug development timelines, CDMOs must be able to scale quickly to progress from early clinical development to validation and commercial launch.

VP of Scientific Consulting John McDermott shares insights on the benefits of evaluating targeted oncology molecules in healthy volunteers and applying an effective platform to accelerate optimization.

Review this 3D screen printing’s potential to revolutionize pharmaceutical manufacturing with scalable, customizable, multi-drug tablets and precise, patient-centric drug release profiles.

For clinical trials, we provide full support from warehousing to returns. Join Ropack's Head of Commercial, Chris Vounasis, for a presentation on our technologies and 2025–2026 capacity.

Consider utilizing our cost-efficient global network and connecting with our team today to streamline your medicinal chemistry and outsourcing needs.

Get an overview of our AI-assisted early phase toolkit, which combines predictive modeling, formulation screening, and data-driven insights to accelerate molecule progression.

Speed up your innovation with software solutions that are designed to streamline operations, reduce costs, and speed time-to-market while ensuring compliance and data integrity.